Isolated system towards a successful radiotherapy treatment

Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 2, 2010, Pages 123-136

  Moawad, E ^a  

^a Ain Shams University   (Egypt)

Author keywords

Emad; Growth energy; Isolated radiotherapy; Work energy principle

Indexed keywords

8 QUINOLINOL INDIUM IN 111; FLUORODEOXYGLUCOSE F 18; PLACEBO; PYRITHIONE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; BREAST TUMOR; CANCER RADIOTHERAPY; CLINICAL COMPETENCE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DOSIMETRY; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE TUMOR; RADIATION ABSORPTION; RADIATION DOSE; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 79952753167     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-010-0029-9     Document Type: Article

References (40)

1. Graham J, Muhsin M, Kirkpatrick P. (2004) Cetuximab. Nat Rev Drug Discov 3:549-550.
2. Czernin J, Weber WA, Herschman HR. (2006) Molecular imaging in the development of cancer therapeutics. Annu Rev Med 57:99- 118.
3. Thakur ML, Ron Coss. (2003) Role of lipid-soluble complexes in targeted tumor therapy. J Nucl Med 2003;44:1293-1300.
4. Weber WA. (2009) Assessing tumor response to therapy. J Nucl Med 50:1S-10S. doi:10.2967/jnumed.108.057174.
5. Barendswaard EC, Humm JL et al. (2001) Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med 42:1251-1256.
6. ICRU. (1984) Stopping powers for electrons and positrons, report 37. International Commission on Radiation Units and Measurements, Bethesda.
7. Serway RA, Jewett JW. (2008) Physics for scientists and engineers, vol 1, 7th edn. Tomson-Brooks/Cole, Pacific Grove.
8. Smithers DW. (1958) The therapeutic use of radioactive isotopes. Ann R Coll Surg Engl 23(4):238-247.
9. Minchinton A, Tannock I. (2006) Drug penetration in solid tumors. Nat Rev Cancer 6:583-592.
10. Gillies RJ, Gatenby RA. (2007) Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 26:1573.
11. Sullivan R, Graham CH. (2007) Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 26:319-331.
12. Brown JM. (1999) The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:5863-5870.
13. Castello PR, David PS. (2006) Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions: implications for oxygen sensing and hypoxic signaling in eukaryotes. Cell Metab 3:277-287.
14. Kuei-Meng Wu. (2009) A new classification of prodrugs: regulatory perspectives. Pharmaceuticals 2(3):77-81.
15. EnvironmentalChemistry.com. (2010) Periodic table of elements: element iodine-I http://environmentalchemistry.com/yogi/periodic/ I.html.
16. Shleien B, Slaback LA Jr, Birky BK. (1998) Health physics and radiological health handbook, 3rd edn. Williams and Wilkins, Baltimore, pp 6-11.
17. Holden NE. (2005) Table of the isotopes. In: Lide DR (ed) CRC Handbook of chemistry and physics, 85th edn, online version. CRC Press, Boca Raton.
18. Shen DHY, Marsee DK. (2004) Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther 11:161-9. doi:10.1038/sj. gt.3302147.
19. Roberson PL, Buchsbaum DJ. (1995) Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131Iodine-labeled antibody for a colon cancer model. Cancer Res 55:5811S-5816S.
20. Torlakovic G, Grover VK. (2005) Easy method of assessing volume of prostate adenocarcinoma from estimated tumor area: using prostate tissue density to bridge gap between percentage involvement and tumor volume. Croat Med J 46(3):423-428.
21. Shields AF, Mankoff DA. (1998) Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 39:1757-1762.
22. Weber WA, Czernin J, Phelps ME, Herschman HR. (2008) Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol 5:44-54.
23. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. (1993) Metabolic monitoring of breast cancer chemohormono-therapy using positron emission tomography: initial evaluation. J Clin Oncol 11:2101-2111.
24. Hoekstra OS, van Lingen A, Ossenkoppele GJ, Golding R, Teule GJ. (1993) Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography. Eur J Nucl Med 20:1214-1217.
25. Shankar LK, Hoffman JM, Bacharach S et al. (2006) Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059-1066.
26. Thakur ML, McAfee JG. (1984) The significance of chromosomal aberrations in indium-111-labeled lymphocytes. J Nucl Med 25:922-927.
27. Goddu SM, Howell RW, Rao DV. (1995) A generalized approach to absorbed dose calculations for dynamic tumor and organ masses. J Nucl Med 36:1923-1927.
28. Howell RW, Rao DV, Sastry KS. (1989) Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. Med Phys 16:66-74.
29. Howell RW. (1992) Radiation spectra for Auger electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 19:1371-1383.
30. Howell RW, Narra VR, Rao DV. (1992) Absorbed dose calculations for rapidly growing tumors. J Nucl Med 33:277-281.
31. EnvironmentalChemistry.com. (2010) Periodic table of elements: element indium-In http://environmentalchemistry.com/yogi/periodic/In.html.
32. Leroy C. Principles of radiation interaction in matter and detection. 2004.
33. Meiring WJ, van Klinken J, Wichers VA. (1991) Differences between electrons and positrons interacting with detector material. Phys Rev A 44:2960-2967.
34. Hubbel JH. (1982) Photon mass attenuation and energy absorption coefficients from 1keV to 20 MeV. Int J Appl Radiat Isot 33:1269-1290.
35. Kassis AI, Howell RW, Sastry KSR, Adelstein SJ. (1988) Positional effects of Auger decays in mammalian cells in culture. In: Baverstock KF, Charlton DE (eds) DNA damage of Auger emitters. Taylor and Francis, London, pp 1-4.
36. Sastry KSR. (1992) Biological effects of the Auger emitter iodine-125: a review. Report no. 1 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 19:1361-1370.
37. Hofer KG. (1980) Radiation biology and potential therapeutic applications of radionuclides. Bull Cancer 67:343-353.
38. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R et al. (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369-1379.
39. Yau JSY, Chu KS. (2009) Usage of a fixed dose of radioactive iodine for the treatment of hyperthyroidism: one-year outcome in a regional hospital in Hong Kong. Hong Kong Med J 15:267-273.
40. Hindorf C, Linden O, Stenberg L, Tennvall J, Strand SE. (2003) Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. Clin Cancer Res 9:4003S-4006S.